|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500099681 |
|
最近更新日期: Date of Last Refreshed on: |
2025-03-27 09:51:45 |
|
注册时间: Date of Registration: |
2025-03-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
类器官在恶性脑肿瘤临床诊疗中的应用及预后评估研究 |
|
Public title: |
Research on the Application and Prognosis Evaluation of Organoids in the Clinical Diagnosis and Treatment of Malignant Brain Tumors |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
类器官在恶性脑肿瘤临床诊疗中的应用及预后评估研究 |
|
Scientific title: |
Research on the Application and Prognosis Evaluation of Organoids in the Clinical Diagnosis and Treatment of Malignant Brain Tumors |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
缪亦锋 |
研究负责人: |
缪亦锋 |
|
Applicant: |
Yifeng Miao |
Study leader: |
Yifeng Miao |
|
申请注册联系人电话: Applicant telephone: |
+86 158 0085 2583 |
研究负责人电话: Study leader's telephone: |
+86 158 0085 2583 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yifengm@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
yifengm@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市浦东新区浦建路160号7号楼8楼神经外科医生办公室 |
研究负责人通讯地址: |
上海市浦东新区浦建路160号7号楼8楼神经外科医生办公室 |
|
Applicant address: |
Neurosurgery Doctor's Office, 8th Floor, Building 7, No. 160, Pujian Road, Pudong New Area, Shanghai |
Study leader's address: |
Neurosurgery Doctor's Office, 8th Floor, Building 7, No. 160, Pujian Road, Pudong New Area, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院附属仁济医院 |
||
|
Applicant's institution: |
Renji Hospital, School of Medicine, Shanghai Jiao Tong University |
||
|
研究负责人所在单位: |
上海交通大学医学院附属仁济医院 |
||
|
Affiliation of the Leader: |
Renji Hospital, School of Medicine, Shanghai Jiao Tong University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LY2025-028-B |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属仁济医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-02-24 00:00:00 |
||
|
伦理委员会联系人: |
陆麒 |
||
|
Contact Name of the ethic committee: |
Qi Lu |
||
|
伦理委员会联系地址: |
上海市浦东新区浦建路160号 |
||
|
Contact Address of the ethic committee: |
160 Pujian Road, Pudong New Area, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6838 3364 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海交通大学医学院附属仁济医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Renji Hospital, School of Medicine, Shanghai Jiao Tong University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海交通大学医学院附属仁济医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Renji Hospital, School of Medicine, Shanghai Jiao Tong University |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
横向课题,资助单位:相屹(上海)生物医学工程有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Horizontal project Funding unit: Xiangyi (Shanghai) Biomedical Engineering Co., Ltd. |
||||||||||||||||||||||
|
Target disease: |
malignant brain tumors |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1、主要目的 (1)收集来自不同患者的恶性脑肿瘤样本,结合临床数据,建立恶性脑肿瘤诊疗数据库; (2)建立摇床悬浮培养法的类器官培养方法,形成方法标准化流程。 2、次要目的 (1)评估类器官在药物筛选、放疗和电场治疗决策和预后判断中的应用价值,为个体化治疗的临床决策提供科学依据; (2)通过脑肿瘤和类器官数据库,研究恶性脑肿瘤的生物学特性和分子机制,为肿瘤治疗提供新的靶点和策略; (3)促进类器官技术在脑肿瘤研究中的应用和推广。 3、 探索性目的 (1) 探索AI辅助诊断技术; (2) 探索恶性脑肿瘤物理治疗应用前景。 |
||||||||||||||||||||||
|
Objectives of Study: |
Main objectives (1) Collect malignant brain tumor samples from different patients, combine them with clinical data, and establish a diagnosis and treatment database for malignant brain tumors. (2) Establish an organoid culture method using the shaking table suspension culture method and form a standardized process for this method. Secondary objectives (1) Evaluate the application value of organoids in drug screening, decision-making for radiotherapy and electric field therapy, and prognosis judgment, and provide a scientific basis for clinical decision-making of individualized treatment. (2) Through the brain tumor and organoid database, study the biological characteristics and molecular mechanisms of malignant brain tumors, and provide new targets and strategies for tumor treatment. (3) Promote the application and popularization of organoid technology in the research of brain tumors. Exploratory objectives (1) Explore AI-assisted diagnosis technology. (2) Explore the application prospects of physical therapy for malignant brain tumors. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、年龄18周岁至80周岁(包括18周岁和80周岁); 2、病理学提示为恶性脑肿瘤的患者; 3、两性都可; 4、患者本人或家属监护人签署研究知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Aged between 18 and 80 years old (both 18 and 80 years old are included). 2.Patients whose pathology indicates a malignant brain tumor. 3.Both genders are eligible. 4.The patient himself/herself or the family member who serves as the guardian signs the informed consent form for the study. |
||||||||||||||||||||||
|
排除标准: |
1、无病理或诊断不明的颅内占位患者; 2、家属或患者拒绝本研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with intracranial space-occupying lesions who have no pathological diagnosis or whose diagnosis is unclear. 2. Family members or patients refuse to participate in this study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-04-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
上海仁济医院内部平台(2027.12.31,仁济医院MDT数据库平台) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Shanghai Renji Hospital's internal platform (December 31, 2027, Renji Hospital MDT Database Platform) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
应用病例报告表进行数据采集,采用标准化的影像学检查方案,如统一的 MRI 序列(T1 加权像、T2 加权像、增强 T1 加权像等)及扫描参数设置,确保不同时间点和不同医疗机构采集的图像具有可比性。由专业的影像科医生或经过培训的研究人员对影像学图像进行阅片和数据记录,包括肿瘤的最大直径、体积计算(可借助专业的影像分析软件)、肿瘤边缘特征、周围脑组织受累情况等信息,并将数据准确录入数据库。对影像学图像进行数字化存储,建立图像档案与对应的患者数据库信息关联,以便随时回顾和重新分析。 临床数据采集包括详细记录患者的症状表现,如头痛、呕吐、癫痫发作频率、肢体无力程度等症状的变化情况,采用量化的评分系统(如疼痛视觉模拟评分法对头痛程度进行评分)进行记录。记录患者的神经功能评估结果,如 KPS 评分、格拉斯哥昏迷评分(Glasgow Coma Scale,GCS)等,以及其他特定神经功能检查(如认知功能测试、运动协调性测试等)的数据。收集患者的治疗相关信息,包括所接受的手术方式、放疗剂量及范围、化疗药物种类及剂量、靶向治疗药物使用情况等,这些数据将有助于分析不同治疗手段对疗效的影响。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection is carried out using case report forms, and a standardized imaging examination protocol is adopted. For example, unified MRI sequences (such as T1-weighted imaging, T2-weighted imaging, enhanced T1-weighted imaging, etc.) and scanning parameter settings are used to ensure that the images collected at different time points and in different medical institutions are comparable. Professional radiologists or trained researchers review the imaging images and record the data, including information such as the maximum diameter of the tumor, volume calculation (which can be assisted by professional imaging analysis software), the characteristics of the tumor margin, and the involvement of the surrounding brain tissue. Then, the data are accurately entered into the database. The imaging images are digitally stored, and the image archives are associated with the corresponding patient database information, so that they can be reviewed and re-analyzed at any time. Clinical data collection includes detailed records of the patients' symptom manifestations. For example, the changes in symptoms such as headache, vomiting, the frequency of epileptic seizures, and the degree of limb weakness are recorded. A quantitative scoring system (such as the Visual Analogue Scale for Pain to score the degree of headache) is used for recording. Record the results of the patients' neurological function assessment, such as the Karnofsky Performance Status (KPS) score, the Glasgow Coma Scale (GCS), and the data of other specific neurological function examinations (such as cognitive function tests, motor coordination tests, etc.). Collect the treatment-related information of the patients, including the surgical methods received, the radiation dose and range, the types and doses of chemotherapy drugs, and the use of targeted therapeutic drugs. These data will help analyze the impact of different treatment methods on the therapeutic effect. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |